期刊
DIABETES-METABOLISM RESEARCH AND REVIEWS
卷 32, 期 6, 页码 497-511出版社
WILEY
DOI: 10.1002/dmrr.2775
关键词
GLP-1 receptor agonist; intensification; exenatide; lixisenatide; algorithms; latent autoimmune diabetes in adults (LADA)
资金
- Sanofi
A substantial proportion of patients with type 2 diabetes mellitus do not reach glycemic targets, despite treatment with oral anti-diabetic drugs and basal insulin therapy. Several options exist for treatment intensification beyond basal insulin, and the treatment paradigm is complex. In this review, the options for treatment intensification will be explored, focusing on drug classes that act via the incretin system and paying particular attention to the short-acting glucagon-like peptide-1 receptor agonists exenatide and lixisenatide. Current treatment guidelines will be summarized and discussed. (C) 2016 The Authors. Diabetes/Metabolism Research and Reviews Published by John Wiley & Sons Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据